Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic stem cell therapy - Athersys

Drug Profile

Allogeneic stem cell therapy - Athersys

Alternative Names: AMI MultiStem; HLCM 051; MultiStem; PF-05285401; PF-5285401

Latest Information Update: 16 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Athersys
  • Developer Athersys; Case Western Reserve University; Healios; University of Texas Health Science Center at Houston
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes - Unspecified

Highest Development Phases

  • Phase III Stroke
  • Phase II Graft-versus-host disease; Myocardial infarction; Respiratory distress syndrome
  • Phase I Transplant rejection
  • Preclinical Brain injuries; Heart failure; Multiple sclerosis; Peripheral arterial disorders; Spinal cord injuries
  • Discontinued Diabetes mellitus; Mucopolysaccharidosis I; Parkinson's disease; Ulcerative colitis

Most Recent Events

  • 06 Nov 2019 Allogeneic stem cell therapy - Athersys is available for licensing in Europe and other regions as of 16 Nov 2019. https://www.athersys.com/
  • 01 Jul 2019 Athersys completes the phase I/II MUST-ARDS trial in Respiratory distress syndrome (In adults, In the elderly) in USA (IV) (NCT02611609)
  • 14 May 2019 Allogeneic stem cell therapy - Athersys receives Fast Track designation for Respiratory distress syndrome [IV,Infusion] (In the elderly, In adults) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top